Incidence of and Factors Associated with Hypokalemia During Sulbactam/Ampicillin Therapy: A Retrospective Observational Study

Background: The antimicrobial agent sulbactam/ampicillin (SBT/ABPC) is used to treat a wide range of infections; however, hypokalemia has recently attracted attention as an adverse event of SBT/ABPC. Risk factors for this condition have not been fully characterized, and preventive strategies remain unclear. Objective: To investigate the incidence of hypokalemia and identify factors associated with its occurrence during sulbactam/ampicillin therapy. Methods: This single-center retrospective observational study used routinely collected electronic medical record data from hospitalized patients aged ≥ 20 years without hypokalemia at the initiation of SBT/ABPC therapy who received SBT/ABPC for >2 consecutive days at a hospital in Japan between January 1, 2022, and December 31, 2024. Patients undergoing hemodialysis, those with hypokalemia at the initiation of SBT/ABPC therapy, and those lacking the required laboratory or body weight data were excluded. The primary endpoint was the identification of factors associated with hypokalemia during SBT/ABPC therapy. Results: Of the 269 patients who received SBT/ABPC during the study period, 182 were included in the analysis. Hypokalemia occurred in 39 patients (21.4%), of whom 6 had a nadir serum potassium concentration ≤ 3.0 mEq/L. The median time to onset was 4 days (range, 2-13 days). Survival classification and regression tree analysis identified a baseline serum potassium level of ≤3.9 mEq/L ( P < .001) and age >75 years ( P = .008) as factors associated with the occurrence of hypokalemia. Conclusion and relevance: Close monitoring for hypokalemia may be warranted in patients aged > 75 years with a baseline serum potassium level of ≤3.9 mEq/L. In such patients, serum potassium measurement within the first several days after initiation of SBT/ABPC therapy, particularly around days 4 to 5, should be considered.

Authors

Institutions

Publication Details

Journal
Hospital Pharmacy
Published
2026-11-18
DOI
https://doi.org/10.1177/00185787261502964
Primary Topic
Potassium and Related Disorders
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Incidence of and Factors Associated with Hypokalemia During Sulbactam/Ampicillin Therapy: A Retrospective Observational Study

Kazutaka Oda, Kazutaka Uchida, Yoshihiro Nakagawa, Kenshiro Higashi
Hospital Pharmacy
Potassium and Related Disorders
article

Incidence of and Factors Associated with Hypokalemia During Sulbactam/Ampicillin Therapy: A Retrospective Observational Study

Kazutaka Oda, Kazutaka Uchida, Yoshihiro Nakagawa, Kenshiro Higashi
article en

Abstract

Background: The antimicrobial agent sulbactam/ampicillin (SBT/ABPC) is used to treat a wide range of infections; however, hypokalemia has recently attracted attention as an adverse event of SBT/ABPC. Risk factors for this condition have not been fully characterized, and preventive strategies remain unclear. Objective: To investigate the incidence of hypokalemia and identify factors associated with its occurrence during sulbactam/ampicillin therapy. Methods: This single-center retrospective observational study used routinely collected electronic medical record data from hospitalized patients aged ≥ 20 years without hypokalemia at the initiation of SBT/ABPC therapy who received SBT/ABPC for >2 consecutive days at a hospital in Japan between January 1, 2022, and December 31, 2024. Patients undergoing hemodialysis, those with hypokalemia at the initiation of SBT/ABPC therapy, and those lacking the required laboratory or body weight data were excluded. The primary endpoint was the identification of factors associated with hypokalemia during SBT/ABPC therapy. Results: Of the 269 patients who received SBT/ABPC during the study period, 182 were included in the analysis. Hypokalemia occurred in 39 patients (21.4%), of whom 6 had a nadir serum potassium concentration ≤ 3.0 mEq/L. The median time to onset was 4 days (range, 2-13 days). Survival classification and regression tree analysis identified a baseline serum potassium level of ≤3.9 mEq/L ( P < .001) and age >75 years ( P = .008) as factors associated with the occurrence of hypokalemia. Conclusion and relevance: Close monitoring for hypokalemia may be warranted in patients aged > 75 years with a baseline serum potassium level of ≤3.9 mEq/L. In such patients, serum potassium measurement within the first several days after initiation of SBT/ABPC therapy, particularly around days 4 to 5, should be considered.

Hospital Pharmacy
Kumamoto City Hospital (JP), Kumamoto University Hospital (JP), Kumamoto Shinto General Hospital (JP), Kumamoto University (JP)
Potassium and Related Disorders
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon